Control of body fluid volume regarded as a feedback system

1966 ◽  
Vol 4 (6) ◽  
pp. 567-574 ◽  
Author(s):  
M. Nagasaka ◽  
K. Shimizu ◽  
T. Maeda ◽  
Y. Yoshitoshi ◽  
S. Koshikawa ◽  
...  
Keyword(s):  
Body Fluid ◽  
Feedback System ◽  
Fluid Volume ◽  
Body Fluid Volume

scholarly journals A Possible Physiological Role of Atrial Natriuretic Peptide in Body Fluid Volume Regulation

1988 ◽  
Vol 13 ◽  
pp. S62-S68
Author(s):  
Yasunobu Hirata ◽  
Masao Ishii ◽  
Kazushige Fukui ◽  
Hiroshi Hayakawa ◽  
Shin-ichiro Namba ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Volume Regulation ◽  
Body Fluid ◽  
Physiological Role ◽  
Fluid Volume ◽  
Body Fluid Volume ◽  
Fluid Volume Regulation ◽  
Atrial Natriuretic

scholarly journals Dehydration increases the density of C receptors for ANF on rat glomerular membranes

1990 ◽  
Vol 258 (4) ◽  
pp. R1084-R1088 ◽  
Author(s):  
M. C. Kollenda ◽  
A. M. Vollmar ◽  
G. A. McEnroe ◽  
A. L. Gerbes
Keyword(s):  
Binding Sites ◽  
Atrial Natriuretic Factor ◽  
Body Fluid ◽  
Fluid Volume ◽  
Control Group ◽  
Receptor Density ◽  
Lower Plasma ◽  
Short Term ◽  
Salt Loading ◽  
Body Fluid Volume

The present study determined the presence of two types of binding sites for atrial natriuretic factor (ANF), the B and C receptor, on rat glomerular membranes. The effect of short-term salt loading and dehydration on these two receptor populations was investigated consecutively. Salt-loaded rats did not show significant changes in plasma ANF concentrations or in the number of ANF binding sites. Water-deprived rats presented significantly lower plasma ANF concentrations (22.0 +/- 1.9 vs. 34.4 +/- 3.8 fmol/ml, P less than 0.01) and an increase in total receptor density (1,860 +/- 398 vs. 987 +/- 143 fmol/mg protein) as compared with the control group. Differentiation of both receptor populations showed that it was the C receptors that accounted for this increase (1,772 +/- 369 vs. 901 +/- 151 fmol/mg protein, P less than 0.05), whereas B-receptor density was unchanged (89 +/- 31 vs. 87 +/- 44 fmol/mg protein). These data suggest that C receptors for ANF are affected by changes of body fluid volume.

scholarly journals On the question of body fluid volume or sodium status influencing renin release.

1977 ◽  
Vol 267 (2) ◽  
pp. 321-338 ◽  
Author(s):  
J R Blair-West ◽  
A H Brook ◽  
P A Simpson
Keyword(s):  
Body Fluid ◽  
Fluid Volume ◽  
Renin Release ◽  
Body Fluid Volume

Role of Leptin in the Regulation of Body Fluid Volume and Pressures

2003 ◽  
Vol 10 (3) ◽  
pp. 211-218 ◽  
Author(s):  
Prabal K. Guha ◽  
Daniel Villarreal ◽  
Garry P. Reams ◽  
Ronald H. Freeman
Keyword(s):  
Body Fluid ◽  
Fluid Volume ◽  
Body Fluid Volume

Angiotensin II and III upregulate body fluid volume of the clam worm Perinereis sp. via angiotensin II receptors in different manners

Peptides ◽  
2005 ◽  
Vol 26 (12) ◽  
pp. 2452-2457 ◽  
Author(s):  
Ryousuke Satou ◽  
Tsutomu Nakagawa ◽  
Hiroki Ido ◽  
Masayuki Tomomatsu ◽  
Fumiaki Suzuki ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Body Fluid ◽  
Fluid Volume ◽  
Angiotensin Ii Receptors ◽  
Body Fluid Volume

scholarly journals 948-52 Paradoxical Neurohumoral Axis Inhibition After Body Fluid Volume Depletion in Patients with Congestive Heart Failure and Water Retention

1995 ◽  
Vol 25 (2) ◽  
pp. 178A ◽  
Author(s):  
Maurizio D. Guazzi ◽  
Piergiuseppe Agostoni ◽  
G. Battista Perego ◽  
Gianfranco Lauri ◽  
Francesco Giraldi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Body Fluid ◽  
Water Retention ◽  
Fluid Volume ◽  
Volume Depletion ◽  
Body Fluid Volume

Segment-specific resistivity improves body fluid volume estimates from bioimpedance spectroscopy in hemodialysis patients

2006 ◽  
Vol 100 (2) ◽  
pp. 717-724 ◽  
Author(s):  
F. Zhu ◽  
M. K. Kuhlmann ◽  
G. A. Kaysen ◽  
S. Sarkar ◽  
C. Kaitwatcharachai ◽  
...  
Keyword(s):  
Gold Standard ◽  
Total Body Water ◽  
Body Fluid ◽  
Hemodialysis Patients ◽  
Fluid Volume ◽  
Whole Body ◽  
Bioimpedance Spectroscopy ◽  
Specific Resistivity ◽  
Body Fluid Volume ◽  
Total Body

Discrepancies in body fluid estimates between segmental bioimpedance spectroscopy (SBIS) and gold-standard methods may be due to the use of a uniform value of tissue resistivity to compute extracellular fluid volume (ECV) and intracellular fluid volume (ICV). Discrepancies may also arise from the exclusion of fluid volumes of hands, feet, neck, and head from measurements due to electrode positions. The aim of this study was to define the specific resistivity of various body segments and to use those values for computation of ECV and ICV along with a correction for unmeasured fluid volumes. Twenty-nine maintenance hemodialysis patients (16 men) underwent body composition analysis including whole body MRI, whole body potassium (40K) content, deuterium, and sodium bromide dilution, and segmental and wrist-to-ankle bioimpedance spectroscopy, all performed on the same day before a hemodialysis. Segment-specific resistivity was determined from segmental fat-free mass (FFM; by MRI), hydration status of FFM (by deuterium and sodium bromide), tissue resistance (by SBIS), and segment length. Segmental FFM was higher and extracellular hydration of FFM was lower in men compared with women. Segment-specific resistivity values for arm, trunk, and leg all differed from the uniform resistivity used in traditional SBIS algorithms. Estimates for whole body ECV, ICV, and total body water from SBIS using segmental instead of uniform resistivity values and after adjustment for unmeasured fluid volumes of the body did not differ significantly from gold-standard measures. The uniform tissue resistivity values used in traditional SBIS algorithms result in underestimation of ECV, ICV, and total body water. Use of segmental resistivity values combined with adjustment for body volumes that are neglected by traditional SBIS technique significantly improves estimations of body fluid volume in hemodialysis patients.

scholarly journals Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study

2019 ◽  
Author(s):  
Haruka Tamura ◽  
Yoshinobu Kondo ◽  
Kohei Ito ◽  
Masanori Hasebe ◽  
Shinobu Satoh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Composition ◽  
Endothelial Function ◽  
Cardiovascular Events ◽  
Body Fluid ◽  
Microvascular Complications ◽  
Fluid Volume ◽  
Controlled Study ◽  
Body Fluid Volume

Abstract Background : Patients with type 2 diabetes at high risk of cardiovascular events and receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes and death from any cause. Alternatively, treatment with sulfonylurea reduces microvascular complications in diabetes but appears to increase cardiovascular hospitalization or mortality in combination with metformin. In the present study, we therefore assessed the effects of empagliflozin and glimepiride, a sulfonylurea, on endothelial function using flow–mediated dilation (FMD) to estimate arteriosclerosis and cardiovascular events in patients with type 2 diabetes. Methods : In this prospective, randomized, parallel-group comparison, 58 patients with type 2 diabetes were administered metformin and glargine before bedtime for 12 weeks, followed by the random addition of 10 mg empagliflozin or 0.5 mg glimepiride for 12 weeks. The primary outcome was FMD changes (ΔFMDs), which were measured prior to and following 12 weeks of additional treatment. Secondary outcomes comprised changes in metabolic markers and body composition. Results : Analysis of the empagliflozin group ( n = 30) and glimepiride group ( n = 28) showed no significant differences in DFMDs (empagliflozin, −0.19 ± 2.34%; glimepiride, −0.37 ± 2.77%; P ＝ 0.79); likewise, HbA1c changes were similar between the groups. Body weight changes significantly differed (empagliflozin, –0.59 ± 2.5 kg; glimepiride, 1.2 ± 3.0 kg; P = 0.02). However, analysis of body composition revealed that body fluid volume significantly decreased only after empagliflozin treatment (baseline, 35.8 ± 6.8 L; after 12 weeks, –0.33 ± 0.72 L; P = 0.03). Conclusions : Empagliflozin did not improve endothelial function compared with glimepiride in patients with type 2 diabetes, but decreased body fluid volume. This suggested that the coronary protective effect of empagliflozin is not derived by protecting endothelial function but rather from reducing heart failure.

Sign in / Sign up

Export Citation Format

Share Document